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Abstract
Marijuana is one of the most commonly used illicit drugs around the world. It has gained
attention as an alternative medicine to many different disorders. Though initially investigated in
modern medicine for its analgesic and antiemetic properties, cannabis has been recently found to
benefit numerous neurological disorders. Though there are over 100 different cannabinoids
produced by the cannabis plant, Δ9 – tetrahydrocannabinol (THC) has been shown to the most
efficacious phytocannabinoid in neurological disorders. THC has been shown in numerous
previous studies to be effective at treating spasticity caused by multiple sclerosis and spinal cord
injury, as well as seizures. Through binding of the endogenous cannabinoid receptor system
THC is able to affect both the excitatory and inhibitory synapses. Hyperekplexia is an upper
motor neuron disease characterized by hypertonia and exaggerated startle response. In
Hyperekplexia, there is a decrease in inhibitory synapse caused by a loss of glycine receptors.
Because previous studies have demonstrated the efficacy of THC in disorders similar to
hyperekplexia, it should be investigated as a treatment for this disorder as well. This study
demonstrates that in embryonic zebrafish, THC does not detrimentally affect the development of
the synapses needed to complete the startle response. Additionally, this study supports the use of
THC as a treatment option for the alleviation of spasticity caused by hyperekplexia.
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Introduction:
Cannabis sativa was among the first domesticated plant species. It has been used and
distributed across the world for many different purposes (van Backel et. al. 2011). Originally
domesticated in Asia for its textile use, the Cannabis sativa species, or more commonly known
as marijuana, has become increasingly cultivated for medicinal purposes (van Backel et. al.
2011). Records dating back to 2000 B.C. report on marijuana’s application for the treatment of
pain and beriberi, a thiamine deficiency that has neurological symptoms. In the 19th century
Queen Victoria’s personal physician, Sir John Russel Reynolds, praised the plant for its
analgesic and muscle relaxing qualities. It was not until the 1960’s that the first active compound
in Cannabis, Δ9- tetrahydrocannabinol (THC), was characterized (Hagenbach et al. 2007). THC
has been found to be the main psychoactive component of Cannabis, but it is actually only one
of the more than one hundred phytocannabinoids produced by the plant.
THC, as well as other phytocannabinoids, is extremely hydrophobic. These molecules
readily penetrate the central nervous system and cell membranes. It was discovered through the
advent of synthetic cannabinoids, that THC elicits its effects through a receptor-driven
mechanism (Baker et al. 2012, Howlett, 1985). In 1990 the cannabinoid receptor type 1 (CB1)
was cloned and the endogenous cannabinoid system (ECS) was discovered (Matsuda et al 1990).
The ECS is comprised of two G-protein coupled receptors, CB1 and CB2, their neuromodulatory
lipid ligands, and the biosynthetic machinery responsible for receptor and ligand synthesis and
degradation. The CB1 receptor has been found to be the most numerous G protein coupled receptor
within the central nervous system (Baker et. al., 2012, Hill et. al., 2012, Krug II, et. al., 2015,
Lam et. al., 2006). These receptors are typically presynaptically localized and function as
retrograde messengers to decrease synaptic output. Through activation of the Gα subunit,
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cannabinoids are able to inhibit voltage-gated calcium channels and potentiate inward rectifying
potassium channels (Baker et. al., 2012, Hill et al., 2012). Through activation of CB1 receptor,
cannabinoids can regulate synaptic neurotransmission, and effect numerous physiological
processes including those involved in Alzheimer’s, anxiety, epilepsy, multiple sclerosis (MS),
Huntington’s, pain perception, and nervous system function (Hill et. al., 2012). It is now believed
that THC’s therapeutic effects are caused by its binding of the CB1 receptor. For this reason, it
has been researched as a treatment for many neurological and muscular dysfunction disorders.
Multiple clinical studies have been conducted testing the efficacy of THC and CBD
(cannabinidol) containing oromucosal spray as a treatment option for spasticity caused by MS
(Wade et. al., 2010, Zajicek et. al., 2003, Wade et. al., 2006, Karst et. al., 2010, Stott et. al., 2013,
Hagenbach et. al., 2007, Syed et. al., 2014). These studies have found it to be a viable option for
alleviating spasticity, and have shown there are no notable severe side effects. Hagenbach et. al.’s
(2007) research showed that THC significantly decreased spasticity and pain in spinal cord injury
victims. These previous studies and the finding that THC has neuromodulator effects through
binding of the CB1 receptor, lend support to its potential as a treatment option for the spasticity,
or hypertonia, caused by hyperekplexia.
Hyperekplexia, or human startle disease, is a rare but potentially fatal neurological
disorder. It is caused by a loss of function mutation in the genes that encode key components of
the glycinergic synapse (Ganser et. al., 2013, Mine et. al., 2014, Chung et. al., 2010, Becker et
al., 2008, and Villmann et. al., 2009). Glycine is the major inhibitory neurotransmitter in the
vertebrate hindbrain and spinal cord. It functions at the synapse by binding the glycine receptor
to open chloride channels that depolarize the cell, leading to inhibition of neurotransmission, or
relaxation of the muscle. In the majority of hyperekplexia patients, the gene that encodes the
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glycine receptor α1 subunit has a mutation that prevents the receptor protein from recognizing its
ligand (Ganser et. al., 2013, Mine et. al., 2014, Chung et. al., 2010, Becker et al., 2008). The main
symptom of hyperekplexia is an extreme startle reaction to sudden or unexpected movement,
touch or noise. During the startle response, it is common to see an exaggerated head-retraction
reflex, spastic jerking movements, rapid eye blinking, and the patient may fall stiffly. During
these reactions, all voluntary motor control is lost (Ganser et. al., 2013, Mine et. al., 2014).
Additional symptoms of this disorder include: exaggeration of reflexes, unstable walk, and
intermittent apnea, in infants. The current treatment for hyperekplexia is commonly clonazepam,
an anti-anxiety and anti-seizure medication (Chung et. al., 2010). This medication is part of a
family of medications called benzodiazepines (BZD). These medicines work by binding
allosterically, meaning not at the active site, to γ-aminobuteric acid (GABA) receptor subtype A
within the central nervous system. Binding of these receptors by BZD enhances the opening of
chloride channels, which produces a stronger inhibitory response, when GABA, the ligand to
these receptors, binds at the synapse (Riss, J., et. al., 2008). There are currently no known cures
for hyperekplexia, so it is important to continue investigating potential treatments with the hope
of identifying a cure. In previous research it has been demonstrated that THC can be used to
alleviate over excitation caused by MS as well as the spasticity caused by spinal cord injury (Wade
et. al., 2010, Zajicek et. al., 2003, Wade et. al., 2006, Karst et. al., 2010, Stott et. al., 2013,
Hagenbach et. al., 2007, Syed et. al., 2014). Previous research in similar disorders suggest it to
also be a viable treatment option for hyperekplexia. In order to investigate this hypothesis, I chose
the zebrafish model system, in particular the escape behavior and circuitry to understand how
THC can alleviate spasticity.
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Zebrafish (Danio rerio) are a prime model system for testing the effects of THC on
development as well as investigating its potential as a treatment option for hyperekplexia. Because
they are a model organism, zebrafish have a well characterized development as well as a
sequenced and easily manipulated genome. Their nearly translucent body allows for
immunostaining and microscopy, and they are also easily and inexpensively reared, making
replication of the experimental process very simple (Kalueff et. al., 2014, Ganser et. al., 2013,
Krug II et. al., 2015, Lam et. al., 2006). Juvenile zebrafish can absorb molecules like
phytocannabinoids across their skin. The ECS has been found to be highly conserved (Krug II et.
al., 2015). McPartland et al. (2007) found that the ECS of zebrafish serves a similar function to
the mammalian system. It has also been demonstrated, by Ganser et al. (2013), that hyperekplexia
can be modeled in the zebrafish using an antisense oligonucleotide morpholino sequence, or
morpholino, targeting exon 4 of the glra1 gene. For this reason, the morpholino injection was
used again in this study.
A morpholino is a sequence of nucleic acid that resembles RNA (ribonucleic acid) or
DNA (deoxyribonucleic acid) but contains morpholine instead of either of the sugars from these
other nucleic acids polymers. The sequence of bases can be constructed in the morpholino to
complementarily bind a target sequence of mRNA. In doing so, translation is prevented (Ekker,
S., 2000). Morpholinos have been shown to be highly efficacious at knocking down, or
preventing, target proteins from being expressed throughout the entire animal (Nasevicus, A and
Ekker, S., 2000). Morpholino is able to be injected into the yolk of the dividing embryo as early
as the 1-2 cell stage. Such an early injection time ensure all the cells are exposed. As the embryo
uses the yolk to grow and develop the cells become endowed with the morpholino which
preferentially binds the target mRNA in both the cytosol and nucleus to stop the production of a
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desire protein, in this case GLRA1. Because embryos are so small (about 0.7mm) injecting the
yolk of the embryo is achieved using a pulled capillary tube under pressure. This is calibrated to
deliver a consistent amount of morpholino into the egg without rupturing the chorion.
In summary, using zebrafish I was able to investigate the effects of THC on developing
neuronal circuitry. Embryonic zebrafish were treated at different stages of the development, and
the highly characterized startle response was analyzed. Then to test the potential of THC as a
treatment option for hyperekplexia, I created hyperekplexic morphants, through morpholino gene
manipulation techniques. Then treated those morphants with THC at the same developmental
stages previously study and analyzed their startle response. I found that THC does ameliorate the
spasticity caused by hyperekplexia, and found no evidence that THC is detrimental to
development.

Methods:
Fish care and embryo rearing
Experiments were carried out using wild type strains of Danio rerio. Adults were kept on
a 12hour light/12 hour dark circadian cycle, and housed at 28.5oC. Crosses were set up the night
prior to embryo collection in a divided breeding tank. Dividers were lifted at 0900 hours the
following morning and fertilized embryos were collected 1 hour after dividers were lifted.
Embryos were then reared in petri dishes containing system water, the same water the adult fish
were housed in, and kept in a 28.5oC incubator. Embryos were also kept on the same 12 hour
light/12 hour dark cycle. All experiments were conducted in accordance with Kennesaw State
University’s Animal Care and Use committee guidelines.
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Morpholino injection
Splice site-targeted morpholinos (MO) were previously designed against the 3’ acceptor
site of exon 4 in the glycine receptor α 1 (glra1) gene and tested for off-target effects (Ganser et
al., 2013) For control injections, I used the standard control MO provided by Gene Tools (Gene
Tools, LLC; Philomath OR). Mutant injections used MO stock solution that was heated to 65oC
for 5mins and diluted into 1% (w/v) fast-green dye at a 1:1000 ratio. MOs were injected using
filament-lined kwik-fil borosilicate capillary glass (World Precision Instruments, Sarasota FL)
pulled on a P-97 micropipette puller (Sutter Instruments, Novato CA) to a long taper with a fine
tip that was broken back to a 1µm diameter using forceps. Injection was achieved using a
picopump injection rig, calibrated to produce a 100 µm diameter bolus. MOs were injected into
wild type embryos at the 1-2 cell state. Embryos were sorted 5-7 hours after injection so that only
morphants in which the MO bolus had evenly dissipated were treated and analyzed.

THC treatments
Pharmaceutical grade THC (Sigma Aldrich Co, LLC; St. Louis MO) was administered via
vaporization at 60mg/L to entire treatment groups in 50mLs of system water. A proprietary
vaporization chamber was used to treat the animals (Figure 1). Embryos were placed into a sealed
plexi-glass box containing a micropore air stone (Pentair, Aquatic habitats. Apopka, FL). The
stone was connected by aquarium tubing to a Whisper pump in a second sealed plexi-glass box.
The box that housed the Whisper pump also included a titanium nail which was heated to 185oC,
optimal vaporization temperature of THC, by an industrial soldering iron. Both boxes were sealed
to prevent any vapor from escaping. Embryos were exposed to THC at a constant rate for 30
minutes. For treatment embryos were separated into groups and each experimental group was
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treated once at varying developmental stages. Treatment occurred at 3 hpf (hours post
fertilization), 24 hpf, or at 48 hpf (see figure 2).

Behavior analysis
A high-speed camera (FASTEC IMAGING HiSpec1L, Germany) was used to record
spontaneous and touch-evoked behaviors of 24hpf and 48hpf control and treatment fish. Embryos
were manually dechorionated at 24hpf and imaged 1 hour after dechorionation. 24 and 48hpf
embryos that were treated the day of imaging were imaged 1 hour after treatment had ended.
Videos were scored by hand and data was analyzed by one-way ANOVA using Minitab Express
(Minitab Inc. State College PA). Comparisons of significance are all based on p < 0.05.

Immunohistochemistry
Cryosectioning and antibody staining were performed as previously described in Ogino et
al., 2011. 48hpf embryos were embedded in O.C.T compound (Tissue-Tek, Torrance, CA) and
gradually frozen in liquid nitrogen. Samples were sectioned on a cryostat (CM-1850, Leica) and
mounted on Superfrost plus slides (Fisher Scientific, Pittsburgh PA) prior to a 10 min fixation
with 4% (w/v) paraformaldehyde (Sigma Aldrich Co, LLC; St. Louis MO). Anti-glutamate gated
ion channel (clone NMDAR2a, mouse IgG, 1:500) and Anti-Glycine receptor (clone mAB2b,
mouse IgG, 1:500) were used as primary antibodies. Alexa 488- and Alexa 568- conjugated
donkey anti-mouse IgGs were used as secondary antibodies (1:1000, Life Technologies,
Carlsbad, CA). Double staining with anti-glutamate and anti-glycine receptor antibodies was
performed sequentially. Stained sections were mounted in Vectashield/DAPI (Vector
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Laboratories, Burlingame, CA) and images were captured on a confocal microscope using a 1.4
NA 63x oil objective (Zeiss LSM 700, Jena Germany).

Quantification of synaptic staining
Images were processed using Zeiss Zen software 2009 (Zeiss, Jena Germany). Brightness
and contrast were optimized, and concentration of pigment in the spinal cord was measured. These
concentration measurements were analyzed against negative controls to remove background
noise. Final data were compared using ANOVA analysis in Minitab Express (Minitab Inc., State
College PA).

Results
Exposure to THC during development
At 24hpf zebrafish exhibit a coiling behavior in response to a stimulus. When poked the
embryo will bend in one direction, usually opposite the direction the stimulus came from, until
the tail touches the head, called a C-bend. This behavior is promoting the development and growth
of the neural circuitry necessary for the “fight or flight” response that the fish will need to survive.
While the behavior itself is highly characterized the exact timing it takes for the behavior to occur
varies (Kimmel et al., 1974). Control embryos, injected with control morpholino and not further
treated with THC were imaged and analyzed to provide a basis for comparison to morpholino
injected THC treated fish. The average C-bend time for untreated embryos at 24hpf was found to
be 174.76 (±36.53) milliseconds. At 48hpf embryos perform the C-bend response and couple it
to a rhythmic swim pattern away from the stimulus. Control embryos at 48hpf completed this
behavior in 15.93 (±0.71) milliseconds.
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To test the effects of THC on the startle response, embryos were collected and separated
into 3 experimental groups (n≥30). All groups were treated with 60mg/L. At 24 and 48hpf the
startle response was imaged by high speed camera, and then later analyzed. Average C-bend times
for treatment groups were compared to controls using ANOVA analysis. Comparisons of 24hpf
groups can be seen in figure 3. C-bend times were significantly higher in 3hpf and 24hpf treated
fish as compared to control. However, it can be seen in figure 4 that by 48hpf these embryos are
completing the C-bend in an average time similar to the control embryo’s average. Embryos
treated at 48hpf were treated as controls prior to treatment. 1 hour after treatment had concluded,
these embryos were imaged and compared to control. As seen in figure 4, the C-bend time was
significantly higher in this treatment group.
Along with behavior, spasticity and non-responsiveness were counted in each treatment
group to assay for disturbances in circuitry development after THC treatment. Figure 5 shows the
percentage of each population, over all experimental replicates (n≥50), that were labeled nonresponsive or spastic. Embryos that were not able to mount a response after 3 pokes were labeled
as non-responsive. The spastic label was given to embryos that got stuck at the top of the C-bend
for more than 1 second, or continued to bend from side to side more than once per side. It can be
seen in the graph (figure 5) that control embryos had less than 15% of the population labeled as
non-responsive or spastic.
Immunostaining was carried out to investigate the effects of THC on developing excitatory
and inhibitory synapse. Fresh-frozen 48hpf treated and control embryos were sectioned and
double labeled with antibodies recognizing the glycine receptor 1 α subunit and glutamate ion
channel. Figure 9 shows magnified images taken of the spinal cord sections after immunostaining
was completed. Glutamate channels appear red, and are seen at the top of this figure. Glycine
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receptors appear green, in the center of this image. The bottom of figure 10 shows the glycine and
glutamate channels merged together. Each colored dot, or puncta, was counted as a single channel
or receptor. Negative controls in which only the secondary antibodies were applied were used to
ensure only puncta of interest were being counted. The puncta were averaged among each
treatment group. The densities of both glycine receptors and glutamate channels within the
developing spinal cords were compared to control using ANOVA analysis. Control embryos
showed a larger concentration of glutamate channels compared to glycine receptors. THC
treatment groups, by comparison, showed a higher amount of both glycine and glutamate
receptors within the spinal cord, though only embryos treated at 3 and 48hpf were significantly
different from controls.
In summary THC exposed fish showed a marked increase in the amount of time necessary
to perform the startle response, initially after treatments. However within 36 hours after
treatments, they recovered and began behaving normally. When embryos were sequentially
stained, THC exposed fish from 2 of the treatment groups showed significantly different density
of glycine receptor and glutamate ion channel as compared to control embryos.

Hyperekplexia morphant exposure to THC
Morphant embryos were treated by vaporization at 60mg/L of THC, after which their
startle responses were tested. Because of the exaggerated startle response not all embryos were
responsive to the touch stimulus. Fish that were unable to respond to touch after 3 consecutive
pokes, were deemed non responsive. These fish were counted and compared to control groups.
Along with inability to mount a response, some spastic fish would over coil and/or get stuck in
the C-bend and be unable to uncoil for several seconds. These fish were deemed spastic. At 48hpf
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control fish are able to swim in a rhythmic alternating pattern, hyperekplexic fish often have
spastic swim patterns where they bend to the same side consecutively or, because of over
contraction, are unable to swim altogether. These fish were counted as spastic. Percentages of
non-responsive and spastic fish throughout all experimental replicates can be found in figure 8
(n≥50). It can be seen that the number of spastic embryos at both 24 and 48hpf in the morphant
group is greater than that of any other treatment group. Along with counts of non-responsiveness
and spasticity, the average times for embryos to complete initial C-bend were again analyzed.
These averages can be seen in figures 7 and 8. Hyperekplexic behavior was measured at both 24
and 48hpf. At 24hpf hyperekplexic fish completed the C-bend in 758.40(±134.50) milliseconds,
a significant difference from the 174.76 (±36.53) milliseconds of the control group. By 48hpf
these fish were able to complete the C-bend in 165.99 (±26.76) milliseconds. Again this is
significantly different from control time. When morphants were treated with THC, the data shows
a decrease in the average amount of time taken to complete the C-bend, for all treatment groups
at both 24 and 48hpf (figures 3 and 4); however, at 24hpf the only treatment group that is
significantly different from hyperekplexic are the clutches treated at 3hpf. At 48hpf all treatments
groups are significantly different from the Hyperekplexic group.
Immuno-staining was also performed on hyperekplexic experimental groups to investigate
the effect of THC treatment on glycine and glutamate receptors. Figure 10 shows example images
taken from each treatment group. Again the images are zoomed into the spinal cord and contrast
is enhanced. Glutamate channels appear in red and to the top, and glycine receptors appear in
green in the middle pannels. Once more the puncta were quantified after negative controls had
been utilized to remove any background staining and averaged. Untreated morpholino injected
fish showed a reduced density in glycine receptor as compared to control, as well as, an increased
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density of glutamate receptor puncta. All THC treatment groups had an increased density of
glycine receptor in the spinal cord; however only 24hpf treated fish were significantly higher than
hyperekplexic embryos. There was also a significant reduction in the amount of glutamatergic
staining in the spinal cord of all treatment groups compared to untreated hyperekplexic embryos.
Based on both immunohistochemistry and behavioral observation, THC does have an
effect on the spasticity caused by hyperekplexia. All treatment groups showed a decrease in the
amount of time taken to perform the startle response, and the amount of spastic and nonresponsive
embryos was significantly decreased in all three treatment groups. Immuno-staining of both the
glycine and glutamate receptors showed a significant decrease in glutamatergic puncta, and an
increase in glycinergic puncta.

Discussion
My research demonstrates that THC does not appear to detrimentally alter development.
Though THC treated fish showed a markedly longer C-bend time initially after treatment (24hpf
group) and even 24 hours after treatment (3hpf treatment group), by 48 hours post treatment,
embryos from these treatment groups were completing the C-bend and coupled swim in similar
amounts of time to controls. Also when comparing percentages of the population that behaved
spastically or were unresponsive to touch stimulus, THC treatment groups were within 3% of the
control populations. This suggests that the development of the excitatory and inhibitory neurons
utilized by the autonomic nervous system to complete the ‘fight or flight’ response is occurring
properly. The initial increase in behavior time that is seen in the 24 hpf and 48hpf treatment groups
one hour after exposure may be due to continual binding of the CB1 receptors throughout the
nervous system. Hunault et. al.'s (2008) showed that serum concentrations of THC decreased
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slowly even after one hour post exposure. This means THC is still available to bind the receptor.
If CB1 is being continually bound, and has not reached any saturation point, inward rectifying
potassium channels should be continually or perhaps remaining open. Inward rectifying
potassium channels differ from the common leak channels in that they push more potassium into
the cell to re-establish membrane potential (Nichols and Lopatin, 1997). However, constitutively
active inward rectifying potassium channels would hyperpolarize the cell, making depolarization,
or activation of the synapse, delayed. The dosage of THC used in this study at 60mg/L was higher
than the average dose used in previous studies, this was to show that higher dosages were not
harmful to development, and to compensate for the biphasic effect of THC seen in some previous
studies (Baker et al., 2012, Hill et al., 2012, Ruhl et al., 2014). It is possible that at a lower dose,
the lag time seen in the behavior initially after treatment would not be seen. The effects on the
embryos treated at 3hpf merits further investigation. Though the fish began behaving normally at
48hpf, there may be mechanisms that delay the development, such as a decrease in cellular
respiration. During this study Dr. Adrienne King, assistant professor at Kennesaw State
University, performed a respiration test on adult treated zebrafish to investigate the effects of
THC on mitochondrial respiration. This preliminary data, displayed in figure 10, shows that
though THC treated fish were not significantly different from controls, they were taking in more
oxygen than control fish, but appeared unable to convert it to ATP. There have been previous
studies that demonstrated that THC inhibited oxidation and increased oxidative stress (Wolff et.
al., 2015 and Fišar et al., 2014). It may be that though studies have shown the benefit of THC in
many different disease states, the harm could outweigh the good (Hofmann et al., 2013, Syed, et
al., 2014, Wade et al., 2009, Hill et al., 2012, Baker et al., 2012, Zajicek et al., 2003, Wade et al.,
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2006, Karst et al., 2010, Stott et al., 2013, Hagenbach et al., 2007). It is important to note that
there are many studies out there that support both sides of this argument.
The immunohistochemistry performed in this study demonstrated that THC does indeed
have an effect on both the glycinergic and glutamatergic synapses in the spinal cord of developing
embryos. Tagliaferro et al. (2006) showed that treatment with a synthetic CB1 agonist, WIN
55,212-2, increased synaptic densities. My data supports this in that treatment with THC increased
receptor densities compared to control. There have been a number of fairly recent studies
investigating the activation of the cannabinoid receptor system during development (Fried and
Smith, 2001, Campologno et al., 2007). It has been shown to play a role in neural progenitor
differentiation and synaptogenesis (Rubio-Araiz et al., 2008). I believe the data here support this
idea as well. Exposure to THC showed an increase in both glycine receptors and glutamate ion
channels within the developing spinal cord. Survey polls from previous years have deemed
marijuana the number one illicit drug used during pregnancy in the western world (Philipot et al.
2016, Fried and Smith, 2001). It is for that reason that it is so important to continue investigating
the developmental effects of THC and other phytocannabinoids.
THC helps to alleviate spasticity caused by hyperekplexia. As supported by previous work,
(Ganser et.al. 2013) the morpholino knockdown of the glra1 α subunit did produce hyperekplexic
fish that behaved spastically and were mostly non-responsive to touch stimulus.
However, when treated with THC, there was a significant decrease in spastic and nonresponsive
events. Hyperekplexia, though its own separate disorder, is still marked by an upper motor neuron
dysfunction, just like Multiple Sclerosis (MS). There has been a lot of evidence supporting the
efficacy of THC as a treatment for spasticity caused by MS and some investigating its efficacy in
spinal cord injury, my research again supports the findings of these other studies (Syed et. al.,
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2014, Stott et. al., 2013, Karst et. al., 2010, Wade et. al., 2006, Zajicek et. al., 2003, and Wade et.
al., 2010, Hagenbach et al., 2007, Baker et al., 2012, Hofmann et al., 2013). THC/CBD
oromucosal, Sativex has been tested in clinical trials and been found to alleviate spasticity in MS
patients (Syed et. al., 2014, Stott et. al., 2013, Karst et. al., 2010, Wade et. al., 2006, Zajicek et.
al., 2003, and Wade et. al., 2010). Klein et al. 2011, demonstrated that CBD can ameliorate the
psychoactive effects of THC. And it has been proposed that the efficacy of medicinal marijuana
is caused by the cocktail effect of many different phytocannabinoids working in concert (Baker
et al., 2012). It would be of benefit to investigate the efficacy of a combined phytocannabinoid
substance in the treatment of hyperekplexic spasticity. Along with spasticity there are also studies
that support THC as an effective treatment for seizure victims (Hofmann and Frazier, 2013).
These patients are commonly prescribed clonazepam, the same treatment prescribed to
hyperekplexic patients. My research, and previous data from other studies support further
investigating THC as a treatment option for hyperekplexia.
The immunostaining performed on in this study lends more support to the proposition of
THC as a treatment for hyperekplexia. Hyperekplexia embryos showed a decreased density of
glycine receptor and an increase in glutamate density. After treatment of THC all treatment groups
had a decreased density of glutamate and an increased density of glycine. However, only the
24hpf fish had a significant difference from hyperekplexic morphants. If carried into the future it
would be necessary to not only look at the developing spinal cord but also investigate whether
THC exposure has a recue effect on the synapse themselves. Chevaleyre et. al. (2006)
demonstrated that stimulation of the endogenous cannabinoid receptor system can increase
synaptic plasticity and potentially rescue damaged neurons.
Conclusion
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This study supports that THC exposure is not detrimental to development. After the initial
effects of THC exposure have worn off, embryos completing the startle response in a similar time
to controls. This study has also shown that THC can be used to ameliorate the spasticity caused
by hyperekplexia. This research lends more support to the previous studies showing THC’s effects
on spasticity as well as lends support to as yet untested upper motor neuron disorders.
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Figure 1: Schematic of vaporization chamber. This figure shows a schematic representation of
the vaporization chamber invented to treat embryos. The large chamber on the left houses the
THC nail, heated by the soldering iron (in red) and the Whisper air pump (marked by the yellow
box). The pump is attached to the aquarium tubing which exits the left chamber and enters the
right chamber. The right chamber is filled with 500ml of aquarium water. It houses the small
pore air stone, and the embryos during treatment.
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Figure 2: Treatment Ethogram. This figure shows the
breakdown of each experimental step with the time
given by the bar running across the top.
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Figure 3: Escape response at 24hpf after THC treatment. This graph shows the average
times taken to complete the C-bend for THC treatment group. Stars show averages that are
significantly different from control average response time (p>0.05). The legend can be found at
the bottom of the graph. Orange is control. Grey represents the embryos treated with THC 3 hours
post fertilization (hpf). Gold represents embryos treated with THC at 24hpf.
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Figure 4: Escape response at 48hpf after THC treatment. This graph represents the average times
taken to complete the C-bend at 48hpf after THC treatment group. Stars represent averages that
are significantly different from control (p> 0.05). The color key is at the bottom of the graph and
colors follow the previous graph with the addition of embryos treated at 48hpf in black and
morpholino injected embryos treated at 48hpf in yellow. The abbreviations are as follows: MO is
morpholino and COMO is control morpholino, hpf is hours post fertilization, and THC is Δ9tetrahydrocannabinol.
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Figure 5: Spastic and non-responsive THC treatment groups. The above graph shows the spastic
and non-responsive percentages across all experimental replicates for control and THC treatment
groups. The y-axis lists the percentages and the x-axis lists the treatment group. Spastic labeled
percentages are seen in orange and non-responsive are seen in blue.
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Figure 6: Glycine/glutamate expression in THC treated spinal cord sections. These are confocal
images zoomed in on the spinal cord from control and THC treated embryos. Glutamate ion
channels appear in red and glycine receptors appear in green. The images were taken at 40x
magnification.
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Figure 7: Escape response of Hyperekplexic embryos. This graph shows the average times taken
to complete the C-bend for embryos injected with morpholino (MO) to model hyperekplexia. 1
star show averages that are significantly different from control average response time and 2 stars
show averaged that are significantly different from MO(p>0.05). The legend can be found at the
bottom of the graph. Orange is control. Blue represents morpholino (MO). Purple is control
morpholino (COMO). Yellow represents morpholino injected embryos treated at 3hpf, and the
red bar is morpholino injected embryos treated at 24hpf.
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Figure 8: Escape response at 48hpf of Hyperekplexic embryos after THC treatment. This graph
represents the average times taken to complete the C-bend at 48hpf after THC treatment in
morpholino (MO) injected embryos. 1 stars represent averages that are significantly different
from control and 2 stars represent averages significantly different from MO (p> 0.05). The color
key is at the bottom of the graph and colors follow the previous graph with the addition of
embryos treated at 48hpf in Green. The abbreviations are as follows: MO is morpholino and
COMO is control morpholino, hpf is hours post fertilization, and THC is Δ9tetrahydrocannabinol.
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Figure 9: Spastic and non-responsive percentages of injected groups. The above graph shows the
percentages of total populations, including all experimental replications that, that were not
responsive to stimulus (blue) or spastic (orange). Aside from controls, all of these embryos were
injected. COMO represents control morpholino and MO is morpholino injected with no
treatment. Each of the THC treatment groups was injected with morpholino at 1hpf and treated at
their respective treatment times. The y-axis gives the percent of the population and the x-axis
names each treatment group.
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Figure 10: Glycine/glutamate expression in hyperekplexic, THC treated spinal cord sections.
These are confocal images zoomed into the spinal cord from hyperekplexic embryos from each
THC treatment time. MO stands for morpholino injected. Glutamate ion channels appear in red
and glycine receptors appear in green.
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